BarryMGibbonsSBackDMulcahyF. Protease inhibitors in patients with HIV diseases. Clinically important pharmacokinetic considerations. Clin Pharmacokinet1997;32:194–204.
2.
TsengALFoisyMM. Significant interactions with new antiretrovirals and psychotropic drugs. Ann Pharmacother1999;33:461–73.
3.
MichaletsEL. Update: Clinically significant cytochrome P- 450 drug interactions. Pharmacotherapy1998;18:84–112.
4.
McEvoyGK, ed. 1999 AHFS drug information. Bethesda, MD: American Society of Health-System Pharmacists, 1999:604–14.
5.
NaranjoCABustoUSellersEMSandorPRuizIRobertsEAA method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981;30:239–45.
6.
HsuAGrannemanRBertzJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet1998;35: 275–91.
